CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 26 enrolled
Drug / intervention
Melphalan +2 moredrug
Likely dose
Melphalan 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00789256
NCT00789256N/ACompleted
CompareCT.gov

A Pilot Study of Low Dose Melphalan and Bortezomib for Treatment of Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndromes

Dartmouth-Hitchcock Medical Center·interventional·Posted Nov 11, 2008·Updated Oct 24, 2018

In Brief

A clinical study evaluating Melphalan, Bortezomib, and 1 other intervention for Acute Myelogenous Leukemia and Myelodysplastic Syndromes. Completed, enrolled 26 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine the response rate of the combination of bortezomib and melphalan in patients with Acute Myelogenous Leukemia (AML) or high-risk Myelodysplastic Syndromes (MDS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myelogenous Leukemia, Myelodysplastic Syndromes
CountriesUnited States
CollaboratorsMillennium Pharmaceuticals, Inc.

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 11, 2008
Enrollment StartSep 1, 2004
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 17.6 years ago

Interventions

Melphalandrug

Melphalan: 2mg orally, once daily

Bortezomibdrug

Bortezomib: 1.0mg/M2 IV on days 1, 4, 8, 11

Melphalan and bortezomibdrug